Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Kocak, H ^a   Ackermann, S ^a   Hero, B ^a   Kahlert, Y ^a   Oberthuer, A ^a   Juraeva, D ^b   Roels, F ^a   Theissen, J ^a   Westermann, F ^b   Deubzer, H ^b   Ehemann, V ^c   Brors, B ^b   Odenthal, M ^d   Berthold, F ^a   Fischer, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Apoptosis; Class I HOX cluster; Differentiation; Hox C9; Neuroblastoma; Spontaneous regression

Indexed keywords

CYTOCHROME C; HOX C9 PROTEIN; HOX PROTEIN; PHOSPHATIDYLSERINE; UNCLASSIFIED DRUG; CASPASE; HOMEODOMAIN PROTEIN; HOXC9 PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; DOXYCYCLINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL VIABILITY; CHILD; CYTOSOL; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION; HOMEOBOX; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; OUTER MEMBRANE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; TUMOR XENOGRAFT; CANCER STAGING; CELL DIFFERENTIATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; INFANT; METABOLISM; MITOCHONDRION; MORTALITY; NERVOUS SYSTEM TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR CELL LINE; TUMOR REGRESSION; CANCER INHIBITION; CHROMOSOME 12; CONTROLLED STUDY; GENE CLUSTER; HOX C9 GENE; MICROARRAY ANALYSIS; NERVE CELL DIFFERENTIATION; PROTEIN SECRETION;

APOPTOSIS; CASPASES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHILD, PRESCHOOL; CYTOCHROMES C; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; INFANT; MITOCHONDRIA; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASM STAGING; NERVOUS SYSTEM NEOPLASMS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876919708     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.84     Document Type: Article

References (44)

1. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: Rates, trends, and epidemiology. Curr Opin Oncol 2001; 13: 160-166
2. Chamberlain MC. Treatment options for glioblastoma. Neurosurg Focus 2006; 20: E2
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109
4. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95: 777-783
5. Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 2008; 49: 27-35
6. Wu GS, Kim K, el-Deiry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-Tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000; 465: 143-151
7. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20: 205-212
8. Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis 2008; 13: 756-770
9. Kuijlen JM, Mooij JJ, Platteel I, Hoving EW, van der Graaf WT, Span MM et al. TRAILreceptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 2006; 78: 161-171
10. Kuijlen JM, Bremer E, Mooij JJ, den Dunnen WF, Helfrich W. Review: On TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol 2010; 36: 168-182
11. Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper RO. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 2009; 69: 7911-7916
12. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-Inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-853
13. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 2003; 22: 2034-2044
14. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-Induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734-741
15. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-Inducing ligand in vivo. Nat Med 1999; 5: 157-163
16. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006; 11: 1175-1193
17. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335-346
18. Takimoto R, El-Deiry WS. Wild-Type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735-1743
19. Shetty S, Gladden JB, Henson ES, Hu X, Villanueva J, Haney N et al. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 2002; 7: 413-420
20. Vande Velde C, Cizeau J, Dubik D, Alimonti J, Brown T, Israels S et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 2000; 20: 5454-5468
21. Kim JY, Cho JJ, Ha J, Park JH. The carboxy terminal C-Tail of BNip3 is crucial in induction of mitochondrial permeability transition in isolated mitochondria. Arch Biochem Biophys 2002; 398: 147-152
22. Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, Kondo S. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005; 24: 980-991
23. Azad MB, Chen Y, Henson ES, Cizeau J, McMillan-Ward E, Israels SJ et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 2008; 4: 195-204
24. Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003; 22: 4734-4744
25. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000; 97: 9082-9087
26. Bacon AL, Harris AL. Hypoxia-Inducible factors and hypoxic cell death in tumour physiology. Ann Med 2004; 36: 530-539
27. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001; 61: 6669-6673
28. Burton TR, Henson ES, Baijal P, Eisenstat DD, Gibson SB. The pro-cell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: Implications for glioblastoma multiforme tumor cell survival under hypoxia. Int J Cancer 2006; 118: 1660-1669
29. Burton TR, Eisenstat DD, Gibson SB. BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-Inducing factor expression preventing cell death in human malignant gliomas. J Neurosci 2009; 29: 4189-4199
30. Giatromanolaki A, Koukourakis MI, Sowter HM, Sivridis E, Gibson S, Gatter KC et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 2004; 10: 5566-5571
31. Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC et al. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res 2007; 13(2 Pt 1): 467-474
32. Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C et al. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J Pathol 2003; 201: 573-580
33. Delettre C, Yuste VJ, Moubarak RS, Bras M, Robert N, Susin SA. Identification and characterization of AIFsh2, a mitochondrial apoptosis-Inducing factor (AIF) isoform with NADH oxidase activity. J Biol Chem 2006; 281: 18507-18518
34. Lee JW, Jeong EG, Soung YH, Kim SY, Nam SW, Kim SH et al. Immunohistochemical analysis of apoptosis-Inducing factor (AIF) expression in gastric carcinomas. Pathol Res Pract 2006; 202: 497-501
35. Leo C, Horn LC, Hockel M. Hypoxia and expression of the proapoptotic regulator BNIP3 in cervical cancer. Int J Gynecol Cancer 2006; 16: 1314-1320
36. Schmidt-Kastner R, Aguirre-Chen C, Kietzmann T, Saul I, Busto R, Ginsberg MD. Nuclear localization of the hypoxia-regulated pro-Apoptotic protein BNIP3 after global brain ischemia in the rat hippocampus. Brain Res 2004; 1001: 133-142
37. Zinkel SS, Hurov KE, Gross A. Bid plays a role in the DNA damage response. Cell 2007; 130: 9-10; author reply 10-11
38. Wang Q, Gao F, May WS, Zhang Y, Flagg T, Deng X. Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol Cell 2008; 29: 488-498
39. Massaad CA, Portier BP, Taglialatela G. Inhibition of transcription factor activity by nuclear compartment-Associated Bcl-2. J Biol Chem 2004; 279: 54470-54478
40. Karadsheh MF, Delpire E. Neuronal restrictive silencing element is found in the KCC2 gene: Molecular basis for KCC2-specific expression in neurons. J Neurophysiol 2001; 85: 995-997
41. Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y et al. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 2010; 70: 2728-2738
42. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007; 6: 1387-1399
43. Shabason JE, Tofilon PJ, Camphausen K. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 2011; 15: 2735-2744
44. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25: 5404-5416